Aegerion Pharmaceuticals, which is developing small-molecule therapeutics to treat cardiovascular and metabolic disease, announced terms for its IPO on Thursday. The Bridgewater, NJ-based company plans to raise $70 million by offering 4.7 million shares at a price range of $14-$16. At the mid-point of the proposed range, Aegerion Pharmaceuticals will command a market value of $254 million. Aegerion Pharmaceuticals, which was founded in 2005 and has yet to generate product revenue, plans to list on the NASDAQ under the symbol AEGR. Leerink Swann and Lazard Capital Markets are the lead underwriters on the deal.
